Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glaukos Lowers 2020 Guidance, Citing 'Competitive Headwind' In MIGS Business

Executive Summary

Glaukos Corp. said it expects rising competition in the US microinvasive glaucoma surgery (MIGS) space in 2020 from Ivantis along with surgical procedures.

You may also be interested in...



Pacts In Medtech: Glaukos To Distribute Saten's MicroShunt; Acell Signs Distribution Deals

Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in March and April 2019.

Ivantis Hydrus Microstent Beats Glaukos iStent In Glaucoma Study

In the randomized COMPARE trial, eyes treated with Ivantis' Hydrus Microstent were about twice as likely to not need medication than eyes treated with two Glaukos iStent trabecular micro-bypass stents one year after implant  The one-year results of the trial have been accepted for publication in Opthalmology

Philips Announces CEO Succession In Midst Of Massive Recall

Philips CEO Frans van Houten will leave the company in October amid a massive recall of ventilators and related products. Roy Jakobs will succeed van Houten as CEO and president effective 15 October, Philips said.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT126351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel